RNAC FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Cartesian Therapeutics in a report issued on Monday, May 12th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings per share of ($3.92) for the year, down from their previous estimate of ($3.65). The consensus estimate for Cartesian Therapeutics' current full-year earnings is $4.56 per share.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.07). The firm had revenue of $1.10 million during the quarter, compared to analyst estimates of $0.69 million.

Several other analysts also recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Cartesian Therapeutics in a report on Wednesday, April 9th. Needham & Company LLC decreased their price objective on Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $42.50.

Cartesian Therapeutics Price Performance

Shares of NASDAQ:RNAC traded down $0.29 on Wednesday, hitting $9.97. 15,423 shares of the company's stock were exchanged, compared to its average volume of 115,626. Cartesian Therapeutics has a 12 month low of $8.85 and a 12 month high of $41.87. The stock has a market capitalization of $258.76 million, a price-to-earnings ratio of -0.19 and a beta of 0.51. The business's 50 day simple moving average is $12.31 and its two-hundred day simple moving average is $16.64.

Hedge Funds Weigh In On Cartesian Therapeutics

Large investors have recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC bought a new position in Cartesian Therapeutics in the fourth quarter worth about $63,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Cartesian Therapeutics by 22.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,562 shares of the company's stock valued at $82,000 after buying an additional 847 shares during the last quarter. Wells Fargo & Company MN boosted its position in Cartesian Therapeutics by 112.7% in the fourth quarter. Wells Fargo & Company MN now owns 4,847 shares of the company's stock valued at $87,000 after buying an additional 2,568 shares during the last quarter. Corebridge Financial Inc. boosted its position in Cartesian Therapeutics by 32.6% in the fourth quarter. Corebridge Financial Inc. now owns 5,122 shares of the company's stock valued at $92,000 after buying an additional 1,258 shares during the last quarter. Finally, AlphaQuest LLC purchased a new stake in Cartesian Therapeutics in the first quarter valued at approximately $95,000. 86.95% of the stock is currently owned by institutional investors.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.